Tumor location matters: ultracentral spots linked to worse survival in lung metastasis patients

Where a cancer spreads in the lung might change how long a person lives. This analysis looked at patients who received radiation for a specific number of metastases. The team compared those with tumors in the ultracentral area to those with tumors elsewhere. The results were stark. People with ultracentral tumors had significantly shorter times before the cancer grew or spread. Their median time without progression was 5.8 months. In contrast, people with nonultracentral tumors lasted 15.8 months. The difference was very clear and statistically strong. Overall survival followed the same pattern. The median time for the ultracentral group was 29.0 months. For the other group, survival had not yet been reached. This means many people in the second group are still alive. The risk of developing new metastases was also higher for the ultracentral group. About 69.2 percent developed new spots within two years. Only 31.4 percent of the other group did. Safety looked similar for both groups. Rates of serious side effects were low and not significantly different. Local control of the original tumors was also similar. However, the study had limits. It was a single-arm trial with limited data on this specific tumor location. These findings suggest that where the tumor sits is an important factor. Doctors may need to weigh this location carefully when planning treatment. Larger studies are needed to confirm these results before changing standard care.